{"name":"Drugs for Neglected Diseases","slug":"drugs-for-neglected-diseases","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"immunology","drugs":[{"name":"Ravidasvir test formulation produced by Doppel","genericName":"Ravidasvir test formulation produced by Doppel","slug":"ravidasvir-test-formulation-produced-by-doppel","indication":"Other","status":"phase_1"},{"name":"Ambisome + Miltefosine","genericName":"Ambisome + Miltefosine","slug":"ambisome-miltefosine","indication":"Visceral leishmaniasis (kala-azar)","status":"phase_3"},{"name":"E1224","genericName":"E1224","slug":"e1224","indication":"Other","status":"phase_2"},{"name":"LXE408","genericName":"LXE408","slug":"lxe408","indication":"Other","status":"phase_2"},{"name":"Miltefosine and Paromomycin","genericName":"Miltefosine and Paromomycin","slug":"miltefosine-and-paromomycin","indication":"Visceral leishmaniasis","status":"phase_3"},{"name":"SSG and Paromomycin sulphate","genericName":"SSG and Paromomycin sulphate","slug":"ssg-and-paromomycin-sulphate","indication":"Treatment of visceral leishmaniasis","status":"phase_3"},{"name":"liposomal amphotericin B + miltefosine","genericName":"liposomal amphotericin B + miltefosine","slug":"liposomal-amphotericin-b-miltefosine","indication":"Visceral leishmaniasis","status":"phase_3"},{"name":"liposomal amphotericin B + paromomycin","genericName":"liposomal amphotericin B + paromomycin","slug":"liposomal-amphotericin-b-paromomycin","indication":"Visceral leishmaniasis (kala-azar)","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"LPV/RTV pellets and AZT/3TC or ABC/3TC","genericName":"LPV/RTV pellets and AZT/3TC or ABC/3TC","slug":"lpv-rtv-pellets-and-azt-3tc-or-abc-3tc","indication":"HIV-1 infection in pediatric patients (pellet formulation)","status":"phase_3"},{"name":"Lopinavir/ritonavir 4:1","genericName":"Lopinavir/ritonavir 4:1","slug":"lopinavir-ritonavir-4-1","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"marketed"},{"name":"lopinavir with ritonavir in 1:1 ratio","genericName":"lopinavir with ritonavir in 1:1 ratio","slug":"lopinavir-with-ritonavir-in-1-1-ratio","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Amphotericin B Deoxycholate","genericName":"Amphotericin B Deoxycholate","slug":"amphotericin-b-deoxycholate","indication":"Systemic fungal infections (invasive aspergillosis, candidiasis, cryptococcosis)","status":"marketed"},{"name":"Ambisome and Paromomycin","genericName":"Ambisome and Paromomycin","slug":"ambisome-and-paromomycin","indication":"Visceral leishmaniasis (kala-azar)","status":"phase_3"}]}],"pipeline":[{"name":"Amphotericin B Deoxycholate","genericName":"Amphotericin B Deoxycholate","slug":"amphotericin-b-deoxycholate","phase":"marketed","mechanism":"Amphotericin B binds to ergosterol in fungal cell membranes, creating pores that disrupt membrane integrity and cause cell death.","indications":["Systemic fungal infections (invasive aspergillosis, candidiasis, cryptococcosis)","Leishmaniasis","Amphotericin B-responsive fungal infections in immunocompromised patients"],"catalyst":""},{"name":"Ravidasvir test formulation produced by Doppel","genericName":"Ravidasvir test formulation produced by Doppel","slug":"ravidasvir-test-formulation-produced-by-doppel","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ambisome + Miltefosine","genericName":"Ambisome + Miltefosine","slug":"ambisome-miltefosine","phase":"phase_3","mechanism":"Ambisome (liposomal amphotericin B) disrupts fungal cell membranes while miltefosine inhibits phosphatidylcholine synthesis, together providing synergistic antileishmanial and antifungal activity.","indications":["Visceral leishmaniasis (kala-azar)","Cutaneous leishmaniasis"],"catalyst":""},{"name":"Ambisome and Paromomycin","genericName":"Ambisome and Paromomycin","slug":"ambisome-and-paromomycin","phase":"phase_3","mechanism":"Ambisome (liposomal amphotericin B) disrupts fungal cell membranes by binding ergosterol, while paromomycin is an aminoglycoside antibiotic that inhibits protein synthesis in parasites.","indications":["Visceral leishmaniasis (kala-azar)","Fungal infections in immunocompromised patients"],"catalyst":""},{"name":"E1224","genericName":"E1224","slug":"e1224","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LPV/RTV pellets and AZT/3TC or ABC/3TC","genericName":"LPV/RTV pellets and AZT/3TC or ABC/3TC","slug":"lpv-rtv-pellets-and-azt-3tc-or-abc-3tc","phase":"phase_3","mechanism":"This combination therapy uses protease inhibitors (lopinavir/ritonavir) to block HIV protease, combined with nucleoside reverse transcriptase inhibitors (AZT/3TC or ABC/3TC) to inhibit viral replication at multiple steps.","indications":["HIV-1 infection in pediatric patients (pellet formulation)"],"catalyst":""},{"name":"LXE408","genericName":"LXE408","slug":"lxe408","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lopinavir/ritonavir 4:1","genericName":"Lopinavir/ritonavir 4:1","slug":"lopinavir-ritonavir-4-1","phase":"marketed","mechanism":"Lopinavir and ritonavir are HIV protease inhibitors that block the viral protease enzyme, preventing the maturation of HIV particles and reducing viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients","HIV-2 infection"],"catalyst":""},{"name":"Miltefosine and Paromomycin","genericName":"Miltefosine and Paromomycin","slug":"miltefosine-and-paromomycin","phase":"phase_3","mechanism":"Miltefosine disrupts parasite cell membranes while paromomycin inhibits protein synthesis, together providing synergistic activity against Leishmania parasites.","indications":["Visceral leishmaniasis","Cutaneous leishmaniasis"],"catalyst":""},{"name":"SSG and Paromomycin sulphate","genericName":"SSG and Paromomycin sulphate","slug":"ssg-and-paromomycin-sulphate","phase":"phase_3","mechanism":"SSG and Paromomycin sulphate work by inhibiting protein synthesis in the parasite.","indications":["Treatment of visceral leishmaniasis"],"catalyst":""},{"name":"liposomal amphotericin B + miltefosine","genericName":"liposomal amphotericin B + miltefosine","slug":"liposomal-amphotericin-b-miltefosine","phase":"phase_3","mechanism":"Liposomal amphotericin B targets fungal cell membranes, while miltefosine targets fungal cell membranes and inhibits sphingosine N-acyltransferase.","indications":["Visceral leishmaniasis"],"catalyst":""},{"name":"liposomal amphotericin B + paromomycin","genericName":"liposomal amphotericin B + paromomycin","slug":"liposomal-amphotericin-b-paromomycin","phase":"phase_3","mechanism":"Liposomal amphotericin B disrupts fungal cell membranes while paromomycin inhibits parasitic protein synthesis, together targeting visceral leishmaniasis parasites.","indications":["Visceral leishmaniasis (kala-azar)"],"catalyst":""},{"name":"lopinavir with ritonavir in 1:1 ratio","genericName":"lopinavir with ritonavir in 1:1 ratio","slug":"lopinavir-with-ritonavir-in-1-1-ratio","phase":"marketed","mechanism":"Lopinavir and ritonavir are HIV protease inhibitors that block the viral protease enzyme, preventing the maturation of HIV particles and reducing viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients","COVID-19 (investigational use in some regions during pandemic)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNUUJBUTQ0U3JKUHBqelNyQW55WjdvcnAwUmRzUnMySnllc1ZvenJIX2xpcWtHXzVSRlVjRnJsMkhOa0daenQwR1VXWWZjQ1htVlQzOWxpYk9kSkdtMWJ2a3o1LVpWTGx0bF9PekxpUmlpV01hSjJGMUMtWi0tTWkwMFhPb0pZaUszOTZVNi1zMXRkU2Fx?oc=5","date":"2026-03-19","type":"pipeline","source":"Fortune","summary":"The $3.4 billion lesson Big Pharma needs to learn: its shelved drugs could save millions of patients - Fortune","headline":"The $3.4 billion lesson Big Pharma needs to learn: its shelved drugs could save millions of patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE5ZREFwek15dV9pT1lTRnZ5OUxBYW9iYl9oeEF5QjJtZW5UNXpVcmgzckdaVHk5VjNpUUpNUDJQTVRmSTZaQ3dXdHlTQWM1S01vd1Q5NTVncnRPSHYtcFdNZWJBTzVHb0tiRi1EMWRQVEw?oc=5","date":"2025-11-20","type":"pipeline","source":"Financial Times","summary":"Neglecting infectious diseases is a market failure - Financial Times","headline":"Neglecting infectious diseases is a market failure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQd0pHTVVVUDhFLVBRWDNneF9zcUJLSWF5eWJjM1Q0c1FZV0Q3SnFUenNOcW9WTUpkN0pKZEVBMFRDQTNBRnZuLVlYb2h1OVNmYmgxVVFuZDNHSDh0djIwZkpjcGpqc3pBNHpJNmpxOXlOLTZveUVKUHNhTzFwUGpqOXkydE9CRTBCV2RoWE8wUXZ6OU55Z0RuUzFSRV9Xa19hN09n?oc=5","date":"2025-10-09","type":"pipeline","source":"statnews.com","summary":"Pharma’s shift away from infectious disease research could spell disaster for the world’s poorest people - statnews.com","headline":"Pharma’s shift away from infectious disease research could spell disaster for the world’s poorest people","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1yUTE4NzFrV2c4cEJQOU1RUWt2RFJsOXBLa2NHRjhxQ3BVeTRGaTBaZm5Zd1dtV1FfNGZPeFRlZFYwc1lKVkNkWmtHZDUxWkFsOVVzRGZSTVZZX2JoUk1J?oc=5","date":"2025-09-30","type":"pipeline","source":"nature.com","summary":"Drug development for neglected diseases must account for kids - nature.com","headline":"Drug development for neglected diseases must account for kids","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE1LSC1EYUE2emt0LXBvMUV3eGl1UF96VnNGM2NzWHl2SGNJeV9KdjFDTF9ueERsMW40N19POVFZLVBhNlFYaTlJQjhMTDItcjJrRkVUdzlfckFFTFk?oc=5","date":"2025-09-02","type":"pipeline","source":"Fierce Pharma","summary":"Novartis - Fierce Pharma","headline":"Novartis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPeEkxQ3hPOGhmUHg5djFKV3JMX1ZpSHRHQkJKRU5MQzNRRV94eW55VnMtRkcxclNHR21ZNld0MnZUdkZLWUdQLXJOMlVPd19QZERjbFlyOXZGR2Z4TkU0cjBDaGdxb003OUxfZTdTUmM1c1Z4Sk1ZcUdKWVcyMzJLMG5xc2tOWVNEazNCUXdQN3J1QWMwWk5Z?oc=5","date":"2025-08-18","type":"pipeline","source":"Devex","summary":"TICAD spotlight: Japan’s pharma commitment to global health - Devex","headline":"TICAD spotlight: Japan’s pharma commitment to global health","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNZXhQUjJTeXNyMElGajhmcENoVUI4UVFCQmFqS3hoWjhQMUVQbU4zQ0lfTzRrMURBWWNjbmFMTUZqYV9jbGI3MlR5VGtVOWotRkwwRE16ZmpYN2xOUHhmeGFjY25ncTNZc3VMcmJSbktwSkthVVRaSWVBMWhlQzJ1MTVvUURaRUszQ2VMaHU5SHNWNThfTjRhWHB3aTVRU29pUFVRTnFiZmFZeVp2d2pRcldUUkRnbWZ4by1oZw?oc=5","date":"2025-06-05","type":"pipeline","source":"NPR","summary":"'Neglected tropical diseases' now face even more neglect - NPR","headline":"'Neglected tropical diseases' now face even more neglect","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPSFAzellIMHlfT3dYTkVHZ0NOYlZQbHkyeDZqWDhwNWRKQkk3TWFkS0dKSmZtUjc2RnRnclAtX21fOEdLdzhHaEtWWmtyNVgzN0lya3hlaWRqZ00wUHVYcW0yOFJpSUFtbnlZTWtTNVpycWx1Q3ZYOGhmNTFvY3lja3RPU2tQa3VSOVE?oc=5","date":"2024-09-02","type":"pipeline","source":"Gavi, the Vaccine Alliance","summary":"AI sifts Africa’s natural remedies for drug discovery - Gavi, the Vaccine Alliance","headline":"AI sifts Africa’s natural remedies for drug discovery - Gavi, the Vaccine Alliance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPYkNPeVVCQ1dHdDM1dllTMmtMTEJZUWw5dFRXREtXV1dYUUMwY2E0NVdRUW96blZWaFI4cm5kdFdXQlR5dEFJWDZMbmt1aFd1dE55a2xTZjJ3RVpvUXVqcDlkRHpVQ2l5eW9IUzM4R25LWndIb09tM0lJZG1yWHdKYm4zMS1XX1E1ZTdFdzE4M2pRSXlWTVptNVMwYmZ4aWFJ?oc=5","date":"2022-06-22","type":"pipeline","source":"BioPharma Dive","summary":"Novartis to invest $250M in tropical disease drug research - BioPharma Dive","headline":"Novartis to invest $250M in tropical disease drug research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNYUpyX0o3ZHVJSGNmR21ONmdwemVZOWU2cVoxTEV6ckF2cXVKMDdHSFMzMG5VemNYYkg4QTMxVjZjbk1tUEgxem42RVZWRDh1SUxzZFhFYjdhRDBzQ2xNYmNzUWV3T1dCZTdFdXlwUEZBcVM2M3ZfSEpza0trRnp5V3hNVEVac2c5VVI4?oc=5","date":"2020-11-13","type":"pipeline","source":"Global Citizen","summary":"How Pharmaceutical Companies Have Helped Tackle Neglected Tropical Diseases Around the World - Global Citizen","headline":"How Pharmaceutical Companies Have Helped Tackle Neglected Tropical Diseases Around the World","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPSkgzZko4eDJfc0UzVWdsVHZ6NkgwaWswbVN6clV1VmlsN1V1VXFVS2hPUk5JMm5CTUl2V1VCS2w2V0tGVDNnS216aGlKZUd6akhTZUg5cWFWTzN1UnJET1pXMzBkX2o5V2tvZlNPcngyMHlPMjZLUkdrOE42Nl85cUhTTHV0RVFhaFFGNS1FYjdfSnpjWEE?oc=5","date":"2017-06-07","type":"pipeline","source":"Chemistry World","summary":"Access to drugs: a failure of pharma? - Chemistry World","headline":"Access to drugs: a failure of pharma?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE94U1c2UElDaW5uRkVwcWZReDhyc2Z3M2ZaUzRCTWRpTTlqd3p3dFFNc3RMdmtzTjRhWWdQcDVtNDlRY0Y4bTFNdklHM1AyNjA3TkdWdHFxeURLalJDRDRocHFGMlZWMlh2OWstZWhsUUZGbkU?oc=5","date":"2011-10-26","type":"pipeline","source":"World Intellectual Property Organization (WIPO)","summary":"Leading Pharmaceutical Companies & Research Institutions Offer IP and Expertise for use in Treating Neglected Tropical Diseases as Part of WIPO Re:Search - World Intellectual Property Organization (WI","headline":"Leading Pharmaceutical Companies & Research Institutions Offer IP and Expertise for use in Treating Neglected Tropical D","sentiment":"neutral"}],"patents":[],"drugCount":13,"phaseCounts":{"marketed":3,"phase_1":1,"phase_3":7,"phase_2":2},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}